Belite Bio posts basic and diluted loss of $0.75 per share in third quarter
Key Facts
Belite Bio reported a GAAP basic and diluted loss of $0.75 per share in the third quarter of 2026, compared with a loss of $0.65 in the year-earlier period. The company reported the unaudited results in a Nov. 12 statement as part of a financial and operational update on development of its experimental treatment tinlarebant. The figures come as the company approaches its target date for a U.S. Food and Drug Administration decision on the treatment application. An independent analyst estimate for non-GAAP loss per share could not be verified. The available comparison therefore focuses on GAAP loss per share and the company's performance across reported periods.
For the nine months ended Sept. 30, 2026, net loss was $85.6 million, compared with $52.3 million in the same period a year earlier. The comparison reflects a wider loss for the period as Belite continues to develop its clinical programs and prepare for the treatment's commercialization. In the third quarter, other income was $6.7 million, up from $1.3 million a year earlier. The company attributed the increase to interest on deposits and Treasury securities. The item highlights the effect of cash and investment returns on the period's results, but did not prevent the increase in net loss recorded for the nine months.
Chief Executive Tom Lin said the company is focused on commercial readiness as it advances toward the target decision date of Feb. 12, 2027. He added that the company is also seeking to expand international access to tinlarebant. The FDA accepted the treatment's marketing application for STGD1 and granted it priority review in August 2026, according to the company. Belite said the agency will not convene an advisory committee to discuss the application, while the review remains ongoing. That leaves the U.S. regulatory process under review, with the final decision resting with the agency.
Alongside the U.S. review, Belite submitted a regulatory application in Japan in September 2026. In October, it submitted marketing authorization applications in Singapore, the United Kingdom and Switzerland through the Access Consortium framework. These steps expand the treatment's regulatory pathway beyond the United States, while the applications in those markets remain under regulatory review. The company did not provide timelines for decisions by those authorities in the information released. Management links its international expansion to the goal of making tinlarebant available in additional markets, alongside commercial preparations ahead of the U.S. target date.
On the clinical front, the company announced that it had completed target enrollment in the DRAGON II trial, which includes Phase 1b and Phase 2/3, with 73 participants in total, including 15 Japanese participants. Enrollment of 530 participants in the PHOENIX trial for geographic atrophy was also completed. Belite said it expects to conduct an interim analysis of PHOENIX data, without specifying a date for the analysis in its statement. Completion of enrollment moves both trials into participant follow-up and data assessment under their study plans, while results and future timing have not been disclosed. These developments were part of the operational update accompanying the quarterly financial results.
In the market, BLTE shares closed at $155.94 in the Nov. 11, 2026 session, according to EL7 data. The company had announced that its shares began trading on the Nasdaq Global Select Market on Oct. 19, 2026, after transferring from the Nasdaq Capital Market, while retaining the BLTE ticker. The transfer put the shares on the new market one day before the financial results were announced. Available data do not include a verified figure for the stock's move during the session or an explanation for its change that day. The next milestones announced by the company remain the ongoing review of the tinlarebant application and the U.S. target date of Feb. 12, 2027.